Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant vWF in adult ECMO patients with major bleeding
NCT06118372Phase 1Recruiting
- Sponsor
- University of Virginia
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of von Willebrand factor concentrate in acquired von Willebrand syndrome (AvWS) and hemorrhage, sponsored by University of Virginia. Primary endpoint: Serious Adverse Events at 30 days. Started Oct 2024; status: recruiting.
02
Drugs
von Willebrand factor concentrate
03
Conditions
acquired von Willebrand syndrome (AvWS)hemorrhage
Beyond the preview
Go deeper on NCT06118372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06118372.